Cara Therapeutics (CARA) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.

6 brokers have issued 12 month price objectives for Cara Therapeutics' shares. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $15.83 in the next year. This suggests a possible upside of 379.8% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.

Cara Therapeutics' stock was trading at $10.74 on January 1st, 2023. Since then, CARA stock has decreased by 69.3% and is now trading at $3.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CARA earnings forecast.

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company had revenue of $20.27 million for the quarter, compared to analyst estimates of $15.74 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 49.31% and a negative net margin of 195.16%. During the same quarter in the previous year, the business earned ($0.35) EPS.

ETFs with the largest weight of Cara Therapeutics (NASDAQ:CARA) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.09%), Bain Capital Life Sciences Investors LLC (4.08%), Farallon Capital Management LLC (3.70%), State Street Corp (3.53%), Kingdon Capital Management L.L.C. (2.28%) and Dimensional Fund Advisors LP (1.75%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends.

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CARA stock can currently be purchased for approximately $3.30.

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $178.10 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.